Logo

Qiagen Posts 21 Percent Q4 Revenue Increase

Feb 17, 2004

NEW YORK, Feb. 17 (GenomeWeb News) - Qiagen today reported a 21 percent revenue increase, along with a rise in net income and R&D spending, for the fourth quarter ended Dec. 31, 2003.

The company posted revenues of $95.1 million for the fourth quarter of 2003, up from $78.4 million in the year-ago period.

Net income was $9.0 million for the quarter, compared to $1.8 million in the same quarter of 2002 - a 407 percent increase. Net income excluding the effect of relocation and restructuring costs increased 34 percent to $13.0 million from $9.7 million in the same period of 2002.

Qiagen spent $9.1 million on R&D during the fourth quarter, up from $7.7 million in the prior year.

As of Dec. 31, 2003, Qiagen had $99.0 million in cash and cash equivalents, compared to $44.9 million as of Dec. 31, 2002.

Breaking News
The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.